BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masamune A, Hamada S, Kikuta K, Takikawa T, Miura S, Nakano E, Shimosegawa T. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol. 2013;48:602-609. [PMID: 23477656 DOI: 10.3109/00365521.2013.777776] [Cited by in Crossref: 45] [Cited by in F6Publishing: 76] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
2 Papanagnou P, Baltopoulos P, Tsironi M. Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal. Ther Clin Risk Manag 2015;11:807-19. [PMID: 26056460 DOI: 10.2147/TCRM.S82049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242 [PMID: 26600982 DOI: 10.4291/wjgp.v6.i4.235] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
4 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
5 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
6 Louault K, Li RR, DeClerck YA. Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. Cancers (Basel) 2020;12:E3108. [PMID: 33114328 DOI: 10.3390/cancers12113108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
7 Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 2017;9:eaan5616. [PMID: 28978752 DOI: 10.1126/scitranslmed.aan5616] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 31.3] [Reference Citation Analysis]
8 Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett. 2017;391:38-49. [PMID: 28093284 DOI: 10.1016/j.canlet.2016.12.035] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 16.6] [Reference Citation Analysis]
9 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
10 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
11 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
12 Bakhtiari E, Hosseini A, Boroushaki MT, Mousavi SH. Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line. Journal of Chemotherapy 2016;28:314-20. [DOI: 10.1179/1973947815y.0000000055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
14 Bijlsma MF, van Laarhoven HW. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 2015;34:97-114. [PMID: 25566685 DOI: 10.1007/s10555-014-9541-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
15 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
16 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
17 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
18 Suklabaidya S, Dash P, Das B, Suresh V, Sasmal PK, Senapati S. Experimental models of pancreatic cancer desmoplasia. Lab Invest. 2018;98:27-40. [PMID: 29155423 DOI: 10.1038/labinvest.2017.127] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
19 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
20 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
21 Zhang S, Wang Y. Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncol Lett 2018;15:5859-64. [PMID: 29552215 DOI: 10.3892/ol.2018.8002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
22 Schnittert J, Bansal R, Prakash J. Targeting Pancreatic Stellate Cells in Cancer. Trends Cancer 2019;5:128-42. [PMID: 30755305 DOI: 10.1016/j.trecan.2019.01.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
23 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
24 Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. J Cancer Res Clin Oncol 2015;141:933-9. [PMID: 25398651 DOI: 10.1007/s00432-014-1873-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
25 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
26 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, Matsubara S, Uchino R, Yagioka H, Arizumi T, Hamada T, Miyabayashi K, Mizuno S, Yamamoto K, Kogure H, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 2013;31:1294-9. [PMID: 23690239 DOI: 10.1007/s10637-013-9972-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
28 Heinrich MA, Mostafa AMRH, Morton JP, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev 2021;174:265-93. [PMID: 33895214 DOI: 10.1016/j.addr.2021.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sriram K, Salmerón C, Wiley SZ, Insel PA. GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets. Br J Pharmacol 2020;177:2434-55. [PMID: 32060895 DOI: 10.1111/bph.15028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Yoshida N, Masamune A, Hamada S, Kikuta K, Takikawa T, Motoi F, Unno M, Shimosegawa T. Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer. Cancer Lett 2017;390:103-14. [PMID: 28093281 DOI: 10.1016/j.canlet.2017.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
31 Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic cancer and its stroma: A conspiracy theory. World J Gastroenterol 2014; 20(32): 11216-11229 [PMID: 25170206 DOI: 10.3748/wjg.v20.i32.11216] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
32 Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules 2021;11:901. [PMID: 34204306 DOI: 10.3390/biom11060901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503-1523. [PMID: 25071162 DOI: 10.1084/jem.20140692] [Cited by in Crossref: 423] [Cited by in F6Publishing: 418] [Article Influence: 52.9] [Reference Citation Analysis]
34 Emon MA, Domingo-Fernández D, Hoyt CT, Hofmann-Apitius M. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC Bioinformatics 2020;21:231. [PMID: 32503412 DOI: 10.1186/s12859-020-03568-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
36 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
37 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
38 You JC, Jung HS, Kim HS, Lee JH, Moh SH. The Effect of Roots Extract from Potentilla chinensis as Cosmeceutical Material. Journal of Applied Biological Chemistry 2016;59:13-7. [DOI: 10.3839/jabc.2016.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol 2017;116:7-15. [PMID: 28605029 DOI: 10.1002/jso.24643] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
40 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
41 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
42 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
43 Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The Effect of Local Renin Angiotensin System in the Common Types of Cancer. Front Endocrinol (Lausanne) 2021;12:736361. [PMID: 34539580 DOI: 10.3389/fendo.2021.736361] [Reference Citation Analysis]
44 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
45 Kirkegård J, Mortensen FV, Cronin-Fenton D. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study. Br J Cancer 2019;121:622-4. [PMID: 31474760 DOI: 10.1038/s41416-019-0562-y] [Reference Citation Analysis]
46 Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014;50:2570-2582. [PMID: 25091797 DOI: 10.1016/j.ejca.2014.06.021] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
47 Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol. 2014;5:52. [PMID: 24592240 DOI: 10.3389/fphys.2014.00052] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
48 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
49 Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese JG. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Front Oncol 2020;10:621937. [PMID: 33520728 DOI: 10.3389/fonc.2020.621937] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
50 Matters GL, Clawson GA. A Speculative Role for Stromal Gastrin Signaling in Development and Dissemination of Pancreatic Ductal Adenocarcinoma. Pancreat Disord Ther 2013;Suppl 4:003. [PMID: 25346875 DOI: 10.4172/2165-7092.S4-003] [Reference Citation Analysis]
51 Arjmand MH. Elucidating the Association Between the Upregulation of Angiotensin Type 1-Receptors and the Development of Gastrointestinal Malignancies. J Gastrointest Cancer 2021;52:399-406. [PMID: 33174118 DOI: 10.1007/s12029-020-00547-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Key role of pancreatic stellate cells in pancreatic cancer. Cancer Lett. 2016;381:194-200. [PMID: 26571462 DOI: 10.1016/j.canlet.2015.10.035] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 9.7] [Reference Citation Analysis]
53 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
54 Ahmadian E, Khosroushahi AY, Eftekhari A, Farajnia S, Babaei H, Eghbal MA. Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NFkB-mediated apoptosis in hepatocellular carcinoma cell line HepG2. Biomed Pharmacother 2018;99:939-46. [PMID: 29710494 DOI: 10.1016/j.biopha.2018.01.117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
55 Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol 2014;49:605-17. [DOI: 10.1007/s00535-013-0915-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
56 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
57 Carvalho TMA, Di Molfetta D, Greco MR, Koltai T, Alfarouk KO, Reshkin SJ, Cardone RA. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers (Basel) 2021;13:6135. [PMID: 34885243 DOI: 10.3390/cancers13236135] [Reference Citation Analysis]
58 Jungmann F, Kaissis GA, Ziegelmayer S, Harder F, Schilling C, Yen HY, Steiger K, Weichert W, Schirren R, Demir IE, Friess H, Makowski MR, Braren RF, Lohöfer FK. Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Cancers (Basel) 2021;13:2069. [PMID: 33922981 DOI: 10.3390/cancers13092069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
60 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
61 Cannon A, Thompson CM, Bhatia R, Armstrong KA, Solheim JC, Kumar S, Batra SK. Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma. J Gastroenterol 2021;56:689-703. [PMID: 34279724 DOI: 10.1007/s00535-021-01800-4] [Reference Citation Analysis]
62 Apte MV, Xu Z, Pothula S, Goldstein D, Pirola RC, Wilson JS. Pancreatic cancer: The microenvironment needs attention too! Pancreatology. 2015;15:S32-S38. [PMID: 25845856 DOI: 10.1016/j.pan.2015.02.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
63 Pothula SP, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression. Pancreatology 2020;20:409-18. [PMID: 31928917 DOI: 10.1016/j.pan.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
64 Cannon A, Thompson C, Hall BR, Jain M, Kumar S, Batra SK. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer 2018;9:78-86. [PMID: 30108679 DOI: 10.18632/genesandcancer.171] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
65 Mandilaras V, Bouganim N, Yin H, Asselah J, Azoulay L. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer 2017;116:103-8. [PMID: 27846200 DOI: 10.1038/bjc.2016.375] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
66 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Hamada S, Masamune A, Shimosegawa T. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 2013;4:331. [PMID: 24273517 DOI: 10.3389/fphys.2013.00331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
68 Lafaro KJ, Melstrom LG. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Am J Pathol 2019;189:44-57. [PMID: 30558722 DOI: 10.1016/j.ajpath.2018.09.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
69 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
70 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
71 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
72 Li SY, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, Machida T, Maezawa Y, Takemoto M, Yokote K, Kobayashi Y, Takizawa H, Sata M, Yamagishi K, Iso H, Sawada N, Tsugane S, Kobayashi S, Matsushita K, Nomura F, Matsubara H, Sumazaki M, Ito M, Yajima S, Shimada H, Iwase K, Ashino H, Wang H, Goto K, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Iwadate Y, Hiwasa T. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep 2021;11:13450. [PMID: 34188129 DOI: 10.1038/s41598-021-92786-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Lin YT, Wang HC, Tsai MH, Su YY, Yang MY, Chien CY. Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma. Cancer 2021;127:1606-19. [PMID: 33405241 DOI: 10.1002/cncr.33391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
74 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
75 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
76 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
77 Masamune A, Nakano E, Hamada S, Takikawa T, Yoshida N, Shimosegawa T. Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. Scand J Gastroenterol. 2014;49:323-331. [PMID: 24404812 DOI: 10.3109/00365521.2013.876447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
78 Perini MV, Dmello RS, Nero TL, Chand AL. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther 2020;211:107527. [PMID: 32173557 DOI: 10.1016/j.pharmthera.2020.107527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]